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Osteoarthritis (OA) is a common disease characterized by cartilage degeneration and joint 
remodeling. The underlying molecular changes underpinning disease progression are 
incompletely understood. 
We investigated genes and pathways that mark OA progression in isolated primary 
chondrocytes taken from paired intact versus degraded articular cartilage samples across 38 5 
patients undergoing joint replacement surgery (discovery cohort: 12 knee OA, replication 
cohorts: 17 knee OA, 9 hip OA patients). We combined genome-wide DNA methylation, RNA 
sequencing, and quantitative proteomics data.  
We identified 49 genes differentially regulated between intact and degraded cartilage in at 
least two –omics levels, 16 of which have not previously been implicated in OA progression. 10 
Integrated pathway analysis implicated the involvement of extracellular matrix degradation, 
collagen catabolism and angiogenesis in disease progression. Using independent replication 
datasets, we showed that the direction of change is consistent for over 90% of differentially 
expressed genes and differentially methylated CpG probes. AQP1, COL1A1 and CLEC3B were 
significantly differentially regulated across all three –omics levels, confirming their 15 
differential expression in human disease.  
Through integration of genome-wide methylation, gene and protein expression data in 
human primary chondrocytes, we identified consistent molecular players in OA progression 
that replicated across independent datasets and that have translational potential.  
 20 
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INTRODUCTION 
Osteoarthritis (OA) affects in excess of 40% of individuals over the age of 70 years 1, and is a 
leading cause of pain and loss of physical function 2. The molecular mechanisms underlying 
OA remain incompletely understood and there is no curative therapy for OA; disease 
progression culminates in joint replacement surgery. OA is a complex disease, with both 5 
heritable and environmental factors contributing to susceptibility 3.  
 
Cartilage degeneration is one of the key features of OA. Cartilage tissue is readily accessible 
at joint replacement surgery, providing an opportunity to characterize the molecular 
processes underpinning disease development in the right tissue, both to improve our 10 
fundamental understanding of disease biology and to identify novel therapeutic 
opportunities. In recent years, –omics studies in OA have expanded our understanding of 
disease pathogenesis, reviewed in 4-7. Here we apply integrated multi-omics (DNA CpG 
methylation, RNA sequencing and quantitative proteomics) in knee OA tissue to obtain a 
comprehensive molecular portrait of cartilage degeneration (Figure 1a). The fundamental 15 
question here addresses the biological processes underpinning disease progression within 
the OA joint, which is of direct clinical relevance to patients suffering from OA. To achieve 
this, we collected individually-matched pairs of cartilage tissue from patients undergoing 
joint replacement surgery, with one sample demonstrating advanced degenerative change 
and the other demonstrating little or no evidence of cartilage degeneration. The findings 20 
were then replicated in several independent populations of patients undergoing joint 
replacement. By integrating all three of methylation, gene expression, and protein 
abundance data, we discover disease processes with involvement across multiple levels, and 
reveal novel and robustly replicating molecular players with translational potential. 
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METHODS 
For full details of methods see Supplementary Methods online. 
 
Patients and samples 
Osteochondral samples were collected from 38 patients undergoing total joint replacement 5 
for OA (discovery cohort: 12 knee OA patients; 2 separate replication cohorts: 17 knee OA 
patients, 9 hip OA patients). Cartilage was separated from bone and chondrocytes were 
extracted from each sample. DNA, RNA, and protein were extracted from the isolated 
chondrocytes of each sample. All patients provided full written informed consent prior to 
participation. We obtained two cartilage samples from each patient. Knee samples were 10 
scored using the OARSI cartilage classification system 8,9: one sample with high OARSI grade 
signifying high-grade degeneration (“degraded sample”), and one sample with low OARSI 
grade signifying healthy tissue or low-grade degeneration (“intact sample”) (Supplementary 
Fig. S1 online). Hip samples were classified macroscopically and visually as high-grade 
(“degraded”) or low-grade (“intact”), details see Supplementary Methods online. 15 
 
Proteomics (discovery cohort) 
LC-MS analysis was performed on the Dionex Ultimate 3000 UHPLC system coupled with the 
high-resolution LTQ Orbitrap Velos mass spectrometer. Proteins were defined as 
differentially abundant if the absolute median abundance ratio between degraded and 20 
intact samples was ≥0.75, the absolute median abundance ratio was greater than the 
standard deviation of abundance ratios, and the protein was detected in paired samples 
from at least 5 of 11 patients post-QC.  
 
RNA-seq (discovery cohort) 25 
 6
Multiplexed libraries were sequenced on the Illumina HiSeq 2000 (75bp paired-end read 
length) and individual indexed library BAM files were produced. Reads that passed quality 
control (QC) were re-aligned using tophat2 10, and reads aligning to each gene in each 
sample were counted using the HTSeq package 11. Absolute transcript abundance was 
calculated using the FPKM (fragments per kilobase of transcript per million fragments 5 
mapped) measure across 15,418 genes post-QC. We used edgeR v3.0 12 to identify 
differentially expressed genes, applying a generalized linear model for tissue status 
(degraded or intact) with individual ID as covariate, and defined significance at 5% false-
discovery rate (FDR).  
 10 
Methylation (discovery cohort) 
Methylation was assayed using the Illumina 450k BeadChip. Data were parsed and QCed 
using ChAMP 13; the probe beta values were quantile-normalized using the ‘dasen’ method 
from the wateRmelon package 14. Differential methylation on 425,694 probes post-QC was 
tested using the CpGassoc package 15, applying a linear model for tissue status at each probe, 15 
with individual ID as covariate.  
Following previous analyses 16, differentially methylated regions (DMRs) were defined as 
regions of at least 3 probes with FDR≤5% (DMPs) and no more than 3 non-significant probes, 
with no more than 1kb between adjacent probes. We used bedtools 17 to identify genes 
overlapping each DMR, extending gene boundaries to include likely promoter regions.  20 
For a promoter-level analysis, we used the probe annotations from ChAMP to assign 
promoter probes to each gene. After computing the mean beta value in the promoter of 
each gene in each sample, we used a paired t-test to identify genes with differential 
promoter-region methylation between degraded and intact samples. Significance was set at 
5% FDR. 25 
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Replication of gene expression and methylation changes 
Gene expression and DNA methylation in both replication cohorts were measured using the 
same procedure as for the discovery data. We considered the expression of 14,762 genes 
that passed QC across all datasets; this included 332 of 349 genes with FDR≤5% in the knee 
discovery data. 5 
We considered 416,437 probes that passed QC across all datasets; this included 9,723 of 
9,867 probes with FDR≤5% in the knee discovery data (“DMPs”).  
 
In silico replication 
We carried out an additional replication analysis for gene expression changes using an 10 
available published dataset from the ongoing Research Arthritis and Articular Cartilage 
(RAAK) study 18. This dataset comprised a comparison of affected and macroscopically 
preserved OA cartilage from 33 patients undergoing total joint replacement surgery (22 with 
hip OA, 11 with knee OA), measured using the Illumina HumanHT-12 v3 microarrays. 
 15 
Gene set analyses  
We tested whether particular biological gene sets were enriched among significant genes 
from each of the RNA-seq, methylation, and proteomics datasets. We used KEGG 19, 
Reactome 20, and, separately, Gene Ontology (GO) annotations 21. Genes annotated to the 
same term were treated as a “pathway”. Enrichment was assessed using a 1-sided 20 
hypergeometric test, with significance at 5% FDR. Empirical p-values for the enrichments 
were obtained from randomisations. 
 
For each gene set, we asked whether the association across the three –omics datasets 
(calculated as geometric mean of the p-values) was higher than expected by chance, 25 
obtaining empirical p-values from 100,000 randomisations. 
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Data availability 
All genome-wide summary statistics generated in the discovery component of this study are 
available as Supplementary Tables online. All discovery RNA sequencing data are available in 
the EGA repository, https://www.ebi.ac.uk/ega/studies/EGAS00001001203. All discovery 5 
methylation data are available in the EGA repository, 
https://www.ebi.ac.uk/ega/studies/EGAS00001001213. The discovery proteomics data has 
been deposited in the PRIDE archive under study ID PXD002014 [publication in process]. 
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RESULTS 
We compared the degraded and intact tissue across patient-matched samples. 
 
We identified 209 proteins with evidence of differential abundance (Supplementary Table S1 
online): 90 at higher and 119 at lower abundance in the degraded samples. We confirmed 15 
the quality of the data using an orthogonal label-free approach and, separately, Western 
blotting (see Supplementary Note online).  
  
We identified 349 differentially expressed genes: 296 genes showed higher and 53 lower 
expression levels in the degraded samples (Supplementary Table S2 online). One of the most 20 
strongly down-regulated genes in degraded cartilage was CHRDL2. The corresponding 
protein was also found at lower abundance in degraded cartilage and we confirmed its 
expression in cartilage by immunohistochemistry (Supplementary Fig. S2 online). CHRDL2 is 
a bone morphogenetic protein (BMP) inhibitor that has been reported to be lost from 
chondrocytes of the superficial zone and shifted to the middle zone in OA cartilage in a 25 
targeted study 22. 
 9
 
We identified 9,896 differentially methylated probes (DMPs) (Supplementary Table S3 
online), and 271 differentially methylated regions (DMRs) composed of multiple 
differentially methylated CpG sites, overlapping 296 unique genes (Supplementary Table S4 
online).  5 
 
Integration across multiple –omics levels 
Methylation, RNA sequencing, and proteomics 
We identified 49 genes with evidence of differential regulation from at least two of the  
–omics analyses (Supplementary Table S5 online). Three genes demonstrated significant 10 
evidence for involvement in OA progression across all three levels: AQP1, COL1A1 and 
CLEC3B (Figure 1b). All three genes were up-regulated in degraded tissue in both the RNA-
seq and proteomics analyses (Figure 2a). AQP1 and COL1A1 showed a consistent decrease in 
methylation of all CpG probes in their associated DMRs (commensurate with an increase in 
transcription), while the DMR associated with CLEC3B showed evidence of increased 15 
methylation. Using IHC we independently confirmed the presence of AQP1, COL1A1 and 
CLEC3B in articular cartilage chondrocytes (Supplementary Fig. S2 online). We also replicated 
the direction of gene expression change for all three genes in independent data (see below 
and Supplementary Table S6 online).  
 20 
Of the 49 genes with evidence of differential regulation on at least two molecular levels, 33 
add substantive evidence to genes previously reported and 16 genes (33%) have not 
previously been implicated in OA (Supplementary Table S5 online).  
 
Proteomics and RNA sequencing 25 
 10
Among the 209 proteins with evidence of differential abundance in the proteomics data, 31 
were also differentially expressed between degraded and intact samples at the RNA level 
(hypergeometric p=5.3x10-7, Figure 1b). Twenty-six of these 31 genes showed concordant 
directions of changes at both the protein and RNA level (binomial p=0.0002). Five genes 
were over-expressed at the RNA level and less abundant at the protein level in the degraded 5 
tissue (COL4A2, CXCL12, FGF10, HTRA3 and WNT5B); all five are annotated as secreted 
proteins in the Human Protein Atlas 23 (see Supplementary Note online).  
 
Using all samples irrespective of tissue status, we found a significant correlation between 
gene expression levels and protein abundance (Spearman’s rho=0.29, p<2.2x10-16, 10 
Supplementary Note and Supplementary Fig. S3 online). Considering the RNA and protein 
changes in degraded compared to intact samples (Figure 2a), we also identified a significant 
positive correlation (Pearson’s r=0.17, p<2.2x10-16). This correlation became substantially 
higher when we only considered the 31 genes that were differentially expressed in both 
datasets (Pearson’s r=0.43, p=0.01). 15 
 
Methylation and RNA sequencing 
Sixteen of the genes overlapping a DMR were also differentially transcribed (Figure 1b). In 
the direct comparison of methylation and gene expression using all samples irrespective of 
tissue status, we found the expected negative correlation between promoter region 20 
methylation and gene expression (Spearman’s rho=-0.43, p<2.2x10-16, Supplementary Fig. S3 
online). Based on the comparison of intact to degraded cartilage, the log-fold-changes in 
RNA expression and the differences in mean promoter region methylation values 
demonstrated a small but highly significant correlation (Pearson’s r=-0.08, p<2.2x10-16, 
Figure 2b, Supplementary Table S7 online). The correlation became substantially higher 25 
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when we considered the 39 genes with significant differences at both the promoter 
methylation and transcription levels (Pearson’s r=-0.48, p=0.002). 
 
Replication of gene expression and methylation changes 
We found good correlation between the global gene expression log-fold changes and the 5 
methylation log-fold changes estimated in the discovery and in the knee and, separately, hip 
replication data (Figure 3a-b, Pearson r 0.5-0.9, p<10-15) and excellent replication rates for 
differentially expressed genes and probes with differential methylation (Figure 3c-d, over 
90% have same direction of change in replication data and at least 47% reach nominal 
significance, Supplementary Table S8 online).  10 
 
We specifically considered the 49 genes with evidence from at least two –omics levels. Of 
these, 47 had gene expression data in the discovery and both replication datasets; the 
direction of change replicated at nominal significance for 36 genes in the knee and for 26 
genes in the hip replication data (Supplementary Table S6 online). Notably, the direction of 15 
change replicated in at least one of the knee and hip replication datasets at nominal 
significance for 13 of the 16 genes that have not previously been associated with OA 
(Supplementary Table S6 online). 
 
We additionally pursued replication in a further independent, published microarray gene 20 
expression dataset from the RAAK study 18. This study used pooled knee and hip samples, as 
they found good agreement between the pooled and joint-stratified analyses 18; to increase 
power, we also used the pooled data as in silico replication. Despite the difference in 
genomics technology (RNA-seq in discovery, microarray in RAAK), we again found good 
agreement of the log-fold-changes for the differentially expressed genes from the discovery 25 
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data (over 60% have same direction of effect, Pearson r in 0.24-0.43 at p≤0.003, see 
Supplementary Note online). 
 
Pathways involved in OA progression 
We identified biological processes with consistent evidence of involvement in OA 5 
progression at multiple levels (Figure 4, Supplementary Fig. S4 online, Supplementary Tables 
S9-S10 online). A strong theme is cartilage matrix regulation, degeneration, and disassembly.  
 
Positive regulation of ERK1/2 cascade, heparin-binding and platelet activation were also 
enriched at multiple molecular levels and are interconnected through common genes 10 
(Supplementary Note online). We also found enrichment of genes involved in the regulation 
of angiogenesis at multiple levels, implicating pathways involved in blood vessel and nervous 
system formation (NCAM signaling for neurite outgrowth and PDGF signaling). The growth of 
blood vessels and nerves are closely linked processes that share regulatory mechanisms, 
including the ERK cascade and heparin-binding proteins 24. Indeed, histological examination 15 
of the samples we investigated showed greater blood vessel ingrowth in tissues with more 
advanced OA (Supplementary Fig. S1 online).  
 
Drug repurposing potential 
To identify existing drugs that could be repurposed for OA, we searched Drugbank 25 for the 20 
49 genes differentially regulated across at least two –omics levels. We identified ten agents 
with investigational or established actions on nine of the dysregulated proteins, which 
already have Food and Drug Administration Marketing Authorization for use in humans 
(Table 1). Among them are non-steroidal anti-inflammatory agents active against 
prostacyclin synthase (NSAIDs), which already have marketing authorisation for the 25 
symptomatic treatment of OA. Our search also identified phylloquinone (vitamin K1), an 
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agonist of osteocalcin (BGLAP gene). Periostin (POSTN gene), a protein with elevated 
expression in OA in this study and others 26-28, is a vitamin K-dependent protein that induces 
cartilage degeneration 29. A recent study has associated sub-clinical vitamin K deficiency with 
knee OA incidence 30, adding evidence that this compound could be a disease-modifying 
agent in OA.   5 
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DISCUSSION 
Characterisation of the molecular landscape of OA is now increasingly feasible and catalyzed 
by technological advances in functional genomics, and the accessibility of the relevant tissue 
at joint replacement surgery. Indeed, the field of functional genomics in OA is now budding 
31. Previous studies of osteoarthritis have investigated methylation 32,33, transcription 18,34-37, 5 
or protein expression 38,39 separately, or a combination of up to two of these –omics assays 
16,40,41, some with the addition of genetic data 42. By contrast, this study provides a 
systematic analysis of biological changes involved in OA across genome-wide methylation, 
gene and protein expression levels. 
 10 
We identify 49 genes with evidence of changes between intact and degraded cartilage on 
multiple molecular levels, including some novel molecular players in OA. We provide 
robustly-replicating evidence with convergence of all three –omics levels of the involvement 
of AQP1, COL1A1, and CLEC3B in disease progression.  
 15 
AQP1 encodes aquaporin-1, a protein that facilitates water transport across biological 
membranes. Chondrocyte swelling and increased cartilage hydration has been suggested as 
an important mechanism in OA 43. AQP1 has been found to be over-expressed in the 
meniscus of a rat model of knee OA 44 and in degraded compared to intact articular cartilage 
in human patients with knee OA 45. CLEC3B encodes tetranectin, which binds human tissue 20 
plasminogen activator (tPA) 46. CLEC3B has previously been found to be up-regulated in OA 
34,47. COL1A1 is one of several collagens that were differentially abundant at both the RNA 
and protein levels (see Supplementary Table S5 online). Collagens are the main structural 
components of cartilage and collagen dysregulation plays an important role in OA 48,49.  A 
recent study identified up-regulation of COL1A1 in synovium from humans with end-stage 25 
OA, in the synovium of mice with induced OA and in human fibroblasts stimulated with TGF-
 15
β 50. Moreover, the products of AQP1 and CLEC3B are targeted by existing drugs approved 
for human use: aquaporin-1 is inhibited by Acetazolamide, a carbonic anhydrase inhibitor 
diuretic agent, and tetranectin is bound by tenecteplase, a thromobolytic agent (Table 1).   
 
We further identify previously unreported genes with concordant molecular changes in the 5 
degraded tissue on multiple levels, and with robust replication in independent datasets. 
MAP1A and MAP1B were both significantly up-regulated in degraded cartilage at the RNA 
and protein levels (Figure 2a). These proteins are mainly expressed in the brain and involved 
in regulating the neural cytoskeleton 51. Cytoskeletal regulation is thought to be an 
important process in OA 52 and recently these proteins were implicated in bone formation 53. 10 
PXDN was up-regulated at the RNA level, confirmed by replication, and overlapped two 
hypo-methylated DMRs. PXDN encodes peroxidasin, which is secreted into the extracellular 
matrix and catalyses collagen IV cross-linking 54. The other replicated genes not previously 
implicated in OA (Supplementary Table S6 online) have relatively little characterisation. 
ANPEP (aminopeptidase E) is a broad specificity aminopeptidase that has previously been 15 
detected in the synovial fluid of OA patients 55 and therefore has potential as a novel OA 
biomarker. CHRDL2 is a bone morphogenetic protein (BMP) inhibitor that has been reported 
to be lost from chondrocytes of the superficial zone and shifted to the middle zone in OA 
cartilage in a targeted study 22. WNT5B, a ligand for frizzled receptors in the WNT signaling 
pathway, has been found to be differentially transcribed in osteoarthritic bone, consistent 20 
with current understanding that OA is a disease involving both cartilage and bone 56.  
 
We identify extracellular matrix organization, collagen catabolism and angiogenesis as 
biological pathways that have significant association with disease progression, in agreement 
with the consensus findings of previous methylation and gene expression studies of OA 7. 25 
These results corroborate that increased ECM turnover is a crucial component in OA 
 16
pathogenesis. We found suggestive evidence of a link between some of these pathways and 
genetic OA risk loci (see Supplementary Note online, Supplementary Table S11 online). 
These signals would not have been identified directly from GWAS data, highlighting the 
importance of synthesizing information from multiple molecular levels to obtain a more 
powerful integrated view. Follow-up mechanistic studies will be required before causal 5 
relationships between the identified pathways and OA progression can be established. In the 
chondrocyte, we found little evidence of differential inflammatory pathway activity between 
the intact and degraded samples 57,58. This is not surprising, as all of the patients studied 
here had a diagnosis of OA and clinically advanced disease in at least one location within the 
joint. Inflammatory mediators are soluble factors present throughout the joint, to which 10 
both the healthy and the diseased chondrocyte populations are potentially exposed, and for 
which the regulatory molecules may differ compared to the articular cartilage tissue studied 
here. 
 
Based on our discovery data, we estimate that ~95% of significantly different genes 15 
identified in this study are true positives (Supplementary Fig. S5 online). The replication data 
confirm the high true positive rate and yield independent strong evidence for multiple novel 
OA genes. This shows that the gene expression and methylation changes identified are 
robust. Within the constraints of this study, the changes between intact and degraded OA 
cartilage are largely joint-independent. Further work will be needed to narrow down which 20 
individual gene-level differences between intact and degraded cartilage are joint-
independent and which are specific to a joint. This work is complementary to previous 
studies which examined differences in lesion-distant cartilage between joints 59 or by pooling 
intact and degraded cartilage 16, as neither of these studies examined differences between 
intact and degraded cartilage, and whether such differences are joint-independent. 25 
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Notably, this study is a proof-of-concept for integrative deep molecular phenotyping across 
methylation, gene expression, and protein abundance. As such, it was not powered to 
provide an exhaustive list of molecular targets and pathways. Indeed, we estimate that only 
~10% of the true differentially expressed genes are statistically significant in this study 
(Supplementary Fig. S5 online). The sample size could also affect the degree of overlap and 5 
agreement between the methylation, gene expression, and protein abundance (this overlap 
could also be affected by difficulties in assigning the effects of methylation changes to 
genes: for example, it is possible that the expression of a gene is affected by methylation 
changes in a distal enhancer, or that a given gene contains an enhancer region for a different 
gene, and thus methylation of the first gene also affects the expression of the second). 10 
Larger sample sizes will be required for a more powerful characterisation of the molecular 
changes occurring with disease progression. Moreover, investigations of further OA-relevant 
cell types (including synoviocytes and adipocytes) will be necessary to identify disease-
related changes in other tissues, and the biological mechanisms specific to such tissues. 
 15 
In summary, the integrative functional genomics approach undertaken here has identified 
biological changes in disease-relevant tissues, highlighting three genes and several pathways 
that are involved on all three levels examined. Moreover, the approach identified nine genes 
with changes on multiple molecular levels that are already targeted by drugs approved for 
human use, highlighting the potential of discovering targets for intervention. These drugs 20 
have established safety profiles and pharmacokinetic data for use in humans, which would 
shorten the investigative pipeline to clinical use in OA. These agents cover a broad range of 
mechanisms of action and represent novel investigational targets for ‘first in disease’ studies 
of OA progression. Further studies will be necessary to comprehensively characterize the 
molecular signatures of OA.  25 
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FIGURE LEGENDS 
Figure 1. Overview of the genes identified in each –omics experiment and their overlap.  
a) Schematic view of the 3 functional genomics experiments identifying the number of genes 
shortlisted for each. 
b) Venn diagram identifying the number of overlapping shortlisted genes from each 5 
individual experiment. 
 
Figure 2. Comparison of changes identified in the –omics experiments. 
a) Comparison of the log-fold-changes between all genes identified in both the proteomics 
and RNA-seq experiments. Each gene is represented as a single point, and the colour 10 
corresponds to whether the gene is identified as differentially expressed using edgeR in the 
RNA-seq or proteomics experiments, or both. The trend lines are derived from a linear 
regression in each subset. Positive fold changes indicate increased expression in degraded 
samples. 
b) Comparison of RNA-seq log-fold-change, and mean promoter region methylation change. 15 
The trend lines are derived from a linear regression in each subset. Genes are coloured 
according to the results of the RNA-seq and the promoter-region analyses analogously to 
Figure 2a. 
 
Figure 3. Replication of gene expression and methylation changes.  20 
a, b) Replication of gene expression changes (a) and CpG methylation changes (b) in 
independent datasets of samples from patients with knee (left) and hip (right) OA. 
Differentially expressed genes (a, DEGs) and differentially methylated probes (b, DMPs) from 
the discovery data are marked in black; DEGs and DMPs that additionally show nominal 
significance in the replication data are marked in red.  25 
Inset: correlation between log-fold-changes in discovery and replication data. All: all 14,762 
genes (a) or 416,437 probes (b) that passed QC in the knee discovery, knee replication, and 
hip replication data. DEGs: 332 of the 349 genes with FDR≤5% in the knee discovery data 
that also pass QC in both replication datasets; DMPs: 9,723 of the 9,867 probes with FDR≤5% 
in the knee discovery data that also pass QC in both replication datasets. All correlation 30 
values shown have p<10-15.  
c, d) Directional concordance of changes between discovery and replication for the 
differentially expressed genes (c, DEGs) and differentially methylated probes (d, DMPs) from 
the discovery data. Same dir: proportion of DEGs or DMPs with same direction of change in 
the replication data. Same dir and p≤0.05: among DEGs or DMPs with same direction of 35 
change in the replication data, proportion of those that reach nominal significance in the 
replication dataset. 
 
Figure 4. Significantly enriched gene sets in the integrative analysis. 
Only gene sets that contain at least 5 genes from 2 experiments are shown. Asterisks 40 
indicate significant (5% FDR) enrichment for each individual gene-set in an individual –omics 
experiment. 
a) Fold enrichment for KEGG & Reactome pathways significant at 5% FDR in the integrative 
analysis.  
b) Fold enrichment for GO terms significant at 5% FDR in the integrative analysis. 45 
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TABLES 
Table 1. Results of Drugbank 25 (www.drugbank.ca) search for therapeutic compounds with current FDA marketing authorisation for a clinical indication 
and a potential role in OA treatment. 
The mechanisms of action and references are taken from Drugbank. 
gene 
symbol protein compound 
FDA 
marketing 
status 
target specific 
mechanism drug mechanism of action reference 
ANPEP 
Aminopeptidase 
N Ezetimibe Prescription binds protein 
Anti-hyperlipidemic medication. Used to lower cholesterol 
absorption in the small intestine. 
Kramer et al. (2005) PMID: 
15494415 
ANPEP 
Aminopeptidase 
N Icatibant Prescription inhibits protein 
Synthetic peptidomimetic drug consisting of ten amino 
acids, acts as a specific antagonist of bradykinin B2 
receptors. Used in symptomatic treatment of acute attacks 
of hereditary angioedema in adults with C1-esterase-
inhibitor deficiency. 
Bawolak et al. (2006) PMID: 
17026984 
AQP1 Aquaporin-1 Acetazolamide Prescription inhibits protein 
Carbonic anhydrase inhibitor diuretic agent. Used for the 
medical treatment of glaucoma, epileptic seizure, 
idiopathic intracranial hypertension, altitude sickness, 
cystinuria, periodic paralysis, central sleep apnea, and 
dural ectasia. Xiang et al. (2004) PMID: 15169637 
BGLAP Osteocalcin 
Phylloquinone 
(vitamin K1) NA (vitamin) 
agonist, 
carboxylates 
protein 
Fat-soluble vitamin necessary for post-translational 
modification of certain proteins, mostly required for blood 
coagulation. 
Schurgers et al. (2001) PMID: 
11374034 
CLEC3B Tetranectin Tenecteplase Prescription binds protein 
Tissue plasminogen activator (tPA). Used as a thrombollytic 
agent. 
Westergaard et al. (2003) PMID: 
12694198 
CXCL12 
Stromal cell-
derived factor 1 Tinzaparin Prescription binds protein 
Low molecular weight heparin (LMWH). Used in the 
treatment and prophylaxis of venous thrombo-embolism. Koo et al. (2008) PMID: 18991783 
FGFR2 
Fibroblast growth 
factor receptor 2 Palifermin Prescription binds protein
Recombinant human keratinocyte growth factor (KGF). 
Used to treat oral mucositis in patients undergoing cancer 
chemotherapy.
Beaven et al. (2007) PMID: 
17728847
MAP1A 
Microtubule-
associated 
protein 1A Estramustine Prescription 
disrupts 
protein 
A nitrogen mustard linked to estradiol. Used in palliative 
care of prostatic neoplasms. Stearns et al. (1991) PMID: 1647395 
PTGIS 
Prostacyclin 
synthase 
Non-steroidal 
anti-
inflammatory 
agents Prescription inhibits protein  
COX1 and COX2 inhibitors used in the symptomatic 
treatment of OA. Reed et al. (1985) PMID: 3917545 
S100A4 Protein S100-A4 Trifluoperazine Prescription 
inhibits protein 
function 
A phenothiazine with actions similar to chlorpromazine. 
Used as an antipsychotic and an antiemetic. 
Malashkevish et al. (2010) PMID: 
20421509 
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